Ozempic Lawsuit [January 2025 Update] | File a Claim Today!

The Ozempic Lawsuit is ongoing. 

The ongoing multidistrict litigation (MDL) for GLP-1 medications, including Ozempic, Wegovy, and Mounjaro, reached a pivotal moment with the filing of a Master Complaint.

This consolidated filing outlines common allegations against Novo Nordisk and Eli Lilly, claiming the drug makers failed to adequately warn about severe gastrointestinal side effects such as gastroparesis, intestinal obstruction, and ischemic bowel.

These lawsuits involve over 1,200 claims and may grow into tens of thousands as more users link their injuries to these medications.

The Master Complaint details numerous claims, including:

• Failure to Warn
• Fraudulent Concealment
• Negligent Design
• Strict Liability for Design Defects
• Wrongful Death and Loss of Consortium

Judge Karen S. Marston, overseeing the MDL in the Eastern District of Pennsylvania, is expected to approve a Short Form Complaint soon.

This will streamline the filing process for future cases by allowing plaintiffs to adopt the Master Complaint’s allegations while adding specific details about their claims.

Next steps include addressing cross-cutting issues, such as establishing diagnostic evidence standards and preparing for “bellwether” trials, which will help evaluate how juries may respond to the evidence.

While bellwether trial outcomes won’t directly bind other cases, they could shape settlement negotiations for the growing litigation.

If you or a loved one suffered from severe stomach paralysis, bowel obstruction, ileus, or other health issues after taking Ozempic, you may be eligible to file an Ozempic Lawsuit against the drug makers.

Contact the Ozempic Attorneys at TorHoerman Law for a free consultation.

You can also use the chatbot on this page for a free case review to find out if you qualify to file an Ozempic Lawsuit instantly.

The Ozempic Lawsuit is ongoing. 

The Ozempic Lawsuit involves claims that the diabetes medication Ozempic has caused severe gastrointestinal side effects, including gastroparesis (delayed stomach emptying), nausea, and vomiting.

Plaintiffs allege that Novo Nordisk, the drug’s manufacturer, did not adequately warn users and healthcare providers about these risks.

In October, there were 1,090 cases filed in the Ozempic lawsuit.

By November, this number increased to 1,221, with 131 additional filings.

This rise reflects heightened awareness of the drug’s potential risks and more patients coming forward with claims.

Ozempic’s side effects, particularly gastroparesis, can severely impact quality of life, causing chronic nausea and malnutrition in affected individuals.

If you or a loved one suffered from severe stomach paralysis, bowel obstruction, ileus, or other health issues after taking Ozempic, you may be eligible to file an Ozempic Lawsuit against the drug makers.

Contact the Ozempic Attorneys at TorHoerman Law for a free consultation.

You can also use the chatbot on this page for a free case review to find out if you qualify to file an Ozempic Lawsuit instantly.

The Ozempic Lawsuit is ongoing. 

The FDA is currently reevaluating its decision to declare Eli Lilly’s obesity and diabetes drugs, Zepbound and Mounjaro, no longer in shortage, allowing compounding companies to continue producing their versions temporarily.

This development follows a lawsuit filed by the Outsourcing Facilities Association (OFA), which argued that the FDA’s decision contradicted evidence of ongoing supply issues.

The lawsuit, filed in the U.S. District Court for the Northern District of Texas, contends that the FDA’s removal of these drugs from the shortage list violated federal law by not following proper procedures, such as notifying affected companies and allowing for public comment.

In response, the FDA agreed to reassess its position and let compounders continue making the drugs while negotiations proceed.

Both parties are set to file a status report on November 21.

The case highlights ongoing supply chain challenges for popular GLP-1 medicines, like Zepbound, Mounjaro, and Novo Nordisk’s Wegovy, which have seen unprecedented demand.

While Lilly and Novo have invested heavily to increase production, shortages persist, particularly for the lower “starter” doses of Wegovy, the only formulation still listed in shortage by the FDA.

If you or a loved one suffered from severe stomach paralysis, bowel obstruction, ileus, or other health issues after taking Ozempic, you may be eligible to file an Ozempic Lawsuit against the drug makers.

Contact the Ozempic Attorneys at TorHoerman Law for a free consultation.

You can also use the chatbot on this page for a free case review to find out if you qualify to file an Ozempic Lawsuit instantly.

The Ozempic Lawsuit is ongoing. 

The Ozempic Lawsuit involves claims that the diabetes and weight loss medication, Ozempic, has caused severe gastrointestinal issues, including gastroparesis (paralysis of the stomach), nausea, vomiting, and other serious side effects.

The lawsuit alleges that manufacturers Novo Nordisk and Eli Lilly failed to properly warn patients and healthcare providers about the risks associated with using Ozempic and other GLP-1 drugs.

In September, 869 cases were filed in the Ozempic MDL.

By October, the number of pending Ozempic Lawsuits increased significantly to 1,090, an additional 221 filings.

Ozempic and other GLP-1 weight loss drugs, while primarily used to manage blood sugar levels in individuals with type 2 diabetes, have been linked to severe digestive issues, such as gastroparesis (stomach paralysis).

This condition delays the emptying of the stomach, leading to persistent nausea, vomiting, and malnutrition.

If you or a loved one suffered from severe stomach paralysis, bowel obstruction, ileus, or other health issues after taking Ozempic or other similar drugs, you may be eligible to file a lawsuit against the drug makers.

Contact the Ozempic Attorneys at TorHoerman Law for a free consultation.

You can also use the chatbot on this page for a free case review to find out if you qualify to file an Ozempic Lawsuit instantly

The Ozempic Lawsuit is ongoing. 

The ongoing multidistrict litigation (MDL) against pharmaceutical giants Novo Nordisk and Eli Lilly concerning GLP-1 drugs, including Ozempic, Wegovy, Trulicity, and Mounjaro, continues to develop as plaintiffs claim these medications have caused serious gastrointestinal injuries.

The central allegations within this litigation is that the drugs are linked to gastroparesis, a condition that paralyzes stomach muscles.

With over 900 complaints consolidated into this MDL, 85% of the cases cite gastroparesis as a primary injury.

Both sides of the litigation recently presented key scientific evidence during a “science day” session.

This event, common in large-scale pharmaceutical lawsuits, allowed attorneys and experts to share critical data about the drugs, their effects, and the underlying medical science.

Central to the plaintiffs’ argument is the claim that these medications cause gastroparesis, a serious gastrointestinal condition.

The defense, however, argued that the drugs are designed to delay gastric emptying, which is different from gastroparesis.

This distinction is a key point in their case.

Despite these technical arguments, plaintiffs’ attorneys maintain that the real-life impact of the condition on their clients will ultimately be more compelling in court.

No trial date has been set, but the science day laid important groundwork for future proceedings.

If you or a loved one suffered from severe stomach paralysis, bowel obstruction, ileus, or other health issues after taking Ozempic or other GLP 1 drugs, you may be eligible to file an Ozempic Lawsuit against the drug makers.

Contact the Ozempic Attorneys at TorHoerman Law for a free consultation.

You can also use the chatbot on this page for a free case review to find out if you qualify to file an Ozempic Lawsuit instantly.

The Ozempic Lawsuit is ongoing.

A recent report highlights that Ozempic and other weight loss drugs, including Wegovy, have been linked to 162 deaths in the U.S. over the past six years, according to data from the FDA Adverse Event Reporting System (FAERS).

Although these deaths haven’t been definitively proven to be caused by semaglutide, the active ingredient in these drugs, they were mentioned as factors in the fatalities.

The FAERS database has recorded 62,000 adverse reactions to these drugs, with 10,000 classified as serious.

Despite the growing concerns and reports of side effects, including gastrointestinal issues, pancreas inflammation, and gallbladder problems, the drugs continue to be widely used for weight loss.

Furthermore, in the MDL involving Ozempic and other GLP-1 medications, the U.S. District Court is evaluating whether plaintiffs must provide specific diagnostic testing to prove that they developed gastroparesis.

Specific diagnostic testing refers to a medical process where precise tests, such as gastric emptying studies, are used to confirm whether a patient has a particular condition, such as gastroparesis, by objectively measuring how well the stomach empties food into the intestines.

Additionally, the court will consider if the claims are preempted by federal law and determine whether GLP-1 drugs like Ozempic can cause the injuries in question, with decisions expected to impact the progression and potential settlement of these lawsuits.

“Preempted by federal law” means that federal regulations take precedence over state laws, preventing states from enforcing their own laws if they conflict with federal rules.

If you or a loved one suffered from severe stomach paralysis, bowel obstruction, ileus, or other health issues after taking Ozempic, you may be eligible to file an Ozempic Lawsuit against the drug makers.

Contact the Ozempic Attorneys at TorHoerman Law for a free consultation.

You can also use the chatbot on this page for a free case review to find out if you qualify to file an Ozempic Lawsuit instantly.

The Ozempic weight loss litigation is moving forward, with Science Day set to take place soon.

Science Day is a hearing in mass tort cases, where both sides present evidence, typically including scientific studies, key documents, and expert testimonies. 

The purpose of this hearing is to provide the Court with a deeper understanding of the background of the product and the main issues of the case.

Each judge handles Science Day differently, but it is usually one of the first opportunities for the Court to fully engage with the details of the litigation.

The hearing generally lasts several hours, featuring prepared presentations and open dialogue with the Court through a question-and-answer format.

For the Ozempic litigation, Science Day offers insights for all parties involved, giving them a clearer understanding of what the legal proceedings in the coming months will look like.

Following Science Day, Judge Marston has scheduled monthly Case Management Conferences for September, October, November, and December, signaling that this litigation will likely gain momentum as the year progresses

If you or a loved one suffered from severe stomach paralysis, bowel obstruction, ileus, or other health issues after taking Ozempic, you may be eligible to file an Ozempic Lawsuit against the drug makers.

Contact the Ozempic Attorneys at TorHoerman Law for a free consultation.

You can also use the chatbot on this page for a free case review to find out if you qualify to file an Ozempic Lawsuit instantly.

The Ozempic Lawsuit is ongoing. 

The Ozempic Lawsuit has seen an increase in filings, rising from 346 in August to 869 in September.

Ozempic, which contains the active ingredient semaglutide, has been linked to severe gastrointestinal issues, including gastroparesis (delayed stomach emptying) and pancreatitis.

Some users have also reported experiencing thyroid tumors and other serious health complications.

These risks have led to a wave of lawsuits against the manufacturer, Novo Nordisk, with claims that the company failed to provide adequate warnings about these potential dangers.

If you or a loved one suffered from severe stomach paralysis, bowel obstruction, ileus, or other health issues after taking Ozempic, you may be eligible to file an Ozempic Lawsuit against the drug makers.

Contact the Ozempic Attorneys at TorHoerman Law for a free consultation.

You can also use the chatbot on this page for a free case review to find out if you qualify to file an Ozempic Lawsuit instantly.

The Ozempic Lawsuit is ongoing and our lawyers are accepting new clients. 

What is Gastroparesis?

Gastroparesis is a condition where the stomach empties its contents into the small intestine much slower than normal.

Symptoms include nausea, vomiting, bloating, feeling full quickly, and abdominal pain.

It can be caused by various factors, including diabetes, surgeries, infections, and certain medications.

Common Causes of Gastroparesis:

• Idiopathic: No known cause, accounts for about 50% of cases.

• Diabetes: More common in type 1 diabetes but can also occur in type 2

• Post-surgical: Following surgeries that impact the stomach or vagal nerve.

• Postinfectious: Often self-limiting but can lead to long-term issues.

How Does Ozempic Work?

Ozempic (semaglutide) is a medication primarily used to treat type 2 diabetes.

It works by mimicking a hormone called GLP-1, which helps to regulate blood sugar levels.

Ozempic increases insulin production and slows down the rate at which food leaves the stomach, which helps keep blood sugar levels stable.

This slowing effect can also lead to weight loss, as it makes you feel full longer.

Link Between Ozempic and Gastroparesis:

Ozempic slows stomach emptying to help control blood sugar, but this can worsen or trigger gastroparesis in some patients.

This side effect has led to lawsuits against Novo Nordisk for not adequately warning users.

Ozempic, a GLP-1 agonist, mimics a hormone that delays food movement through the digestive tract, causing symptoms like nausea and vomiting.

For those already prone to delayed gastric emptying, Ozempic can exacerbate their condition.

Numerous lawsuits claim that Novo Nordisk should have better communicated the risks of severe gastrointestinal side effects, including gastroparesis.

If you or a loved one suffered from severe stomach paralysis, bowel obstruction, ileus, or other health issues after taking Ozempic, you may be eligible to file an Ozempic Lawsuit against the drug makers.

Contact the Ozempic Attorneys at TorHoerman Law for a free consultation.

You can also use the chatbot on this page for a free case review to find out if you qualify to file an Ozempic Lawsuit instantly.

The Ozempic Lawsuit is ongoing and our lawyers are accepting new clients. 

The Ozempic Lawsuit focuses on claims against Novo Nordisk, the manufacturer of Ozempic, a popular medication used for the treatment of type 2 diabetes.

Plaintiffs in this litigation allege that Ozempic causes severe gastrointestinal issues, including gastroparesis, which can lead to debilitating symptoms such as nausea, vomiting, and severe abdominal pain.

These side effects have prompted numerous individuals to file lawsuits, arguing that Novo Nordisk failed to adequately warn users of these potential risks.

According to recent filings, the number of cases related to the Ozempic Lawsuit has been steadily increasing.

As of August 1st, there are 346 cases pending, the same amount as July.

The lawsuits argue that Novo Nordisk was aware, or should have been aware, of the potential for these severe side effects but failed to provide sufficient warnings to consumers and healthcare professionals.

If you or a loved one suffered from severe stomach paralysis, bowel obstruction, ileus, or other health issues after taking Ozempic, you may be eligible to file an Ozempic Lawsuit against the drug makers.

Contact the Ozempic Attorneys at TorHoerman Law for a free consultation.

You can also use the chatbot on this page for a free case review to find out if you qualify to file an Ozempic Lawsuit instantly.

A recent study suggests that patients taking Ozempic and Wegovy may face an elevated risk of developing non-arteritic anterior ischemic optic neuropathy (NAION), a rare condition causing sudden vision loss.

This study, published in JAMA Ophthalmology, indicates that people with diabetes on semaglutide medications are over four times more likely to develop NAION.

Those who are overweight or obese and take these medications face a sevenfold increase in risk.

Over six years, they identified approximately 100 cases annually, noting the highest risk within the first year of medication use.

Novo Nordisk, the manufacturer of Ozempic and Wegovy, acknowledges the study but states the data does not establish causation. 

Despite the potential risk, NAION remains relatively uncommon compared to the benefits provided by these medications.

The U.S. Food and Drug Administration (FDA) includes vision changes among the possible side effects of semaglutide.

Ongoing trials by Novo Nordisk aim to explore the link between semaglutide use and diabetic retinopathy, with results expected by 2027.

Experts say patients who are taking semaglutide or considering treatment should discuss the risks and benefits with their doctors, especially those who have other known optic nerve problems such as glaucoma or preexisting visual loss.

If you or a loved one used Ozempic or other similar drugs and subsequently developed stomach paralysis, ileus, or other health problems, you may be eligible to file a lawsuit. 

Contact the Ozempic Lawyers at TorHoerman Law for a free consultation. 

You can also use the chatbot on this page to find out if you qualify to file a claim instantly.

A recent study from the University of Copenhagen highlights new concerns about GLP-1 medications, including Ozempic, Wegovy, and Mounjaro, focusing on potential bone density loss.

Published in JAMA Network Open, the study found that using these medications, without combining them with exercise, can lead to a decrease in bone mineral density (BMD) in critical areas like the hips and spine.

Ozempic, initially approved for Type 2 diabetes in 2017, has gained popularity as a weight loss drug, Its active ingredient, semaglutide, is also present in Wegovy, a higher-dose version specifically for weight loss.

Despite aggressive marketing promoting these drugs as safe and effective, GLP-1 medications have been linked to severe health risks, including gastroparesis—a condition where the stomach is paralyzed, leading to long-term gastrointestinal issues.

Thousands of lawsuits have been filed against the manufacturers for allegedly failing to warn about these risks, prioritizing profits over consumer safety.

The latest study by Dr. Simon Birk Jensen and colleagues involved a randomized clinical trial with 195 participants.

The findings revealed that participants who combined GLP-1 treatment with exercise achieved the most significant weight loss while maintaining bone health.

Those who used Victoza alone experienced a decrease in BMD.

The study showed the necessity of exercise to mitigate the decrease in bone mineral density, associated with GLP-1 medications.

If you or a loved one used Ozempic or other similar drugs and subsequently developed stomach paralysis, ileus, or other health problems, you may be eligible to file a lawsuit. 

Contact the Ozempic Lawyers at TorHoerman Law for a free consultation. 

You can also use the chatbot on this page to find out if you qualify to file a claim instantly.

Our lawyers are accepting new clients for the ongoing Ozempic Lawsuit. 

Recent research highlights a significant concern for users of glucagon-like peptide-1 receptor agonists (GLP-1RAs), commonly prescribed in diabetes management.

A study, published in Gastroenterology on March 27, 2024, indicates an increased risk of aspiration pneumonia associated with GLP-1RA use during endoscopic procedures involving propofol sedation and targeting the upper gastrointestinal tract.

The retrospective cohort study analyzed health records from 80 healthcare organizations, involving adults aged 21 to 70 who underwent upper and lower endoscopies between 2018 and 2020.

Results show that GLP-1RA users, defined as individuals with a history of use exceeding six months and with at least two refills within six months prior to the procedure, experienced a higher incidence rate of aspiration pneumonia (0.83%) compared to nonusers (0.63%), corresponding to a hazard ratio of 1.33.

This risk was notably higher in procedures involving propofol sedation, specifically upper GI endoscopies, with no significant risk noted in lower GI procedures.

Dr. Ali Rezaie, Medical Director of Gastroenterology Motility at Cedars-Sinai Medical Center, emphasized the need for context, noting that while the relative risk increases by 33%, the absolute risk remains low at 0.2%.

Conversely, the American Gastroenterological Association has not found evidence to support this precaution in their latest clinical update.

Despite this, some medical centers, including Cedars-Sinai, have begun advising patients to discontinue GLP-1RA use one week prior to elective procedures.

Further guidance is expected as new recommendations are being developed, reflecting a cautious approach towards managing the increased risk of aspiration in GLP-1RA users.

If you or a loved one used Ozempic or other similar drugs and subsequently developed stomach paralysis, ileus, or other health problems, you may be eligible to file a lawsuit. 

Contact the Ozempic Lawyers at TorHoerman Law for a free consultation. 

You can also use the chatbot on this page to find out if you qualify to file a claim instantly.

Our lawyers are accepting new clients for the ongoing Ozempic Lawsuit. 

A federal court in Philadelphia is handling the mass tort lawsuit filed against the manufacturers of Ozempic, Wegovy, and other weight-loss drugs.

The case raises significant concerns about the safety and regulation of these widely prescribed medications.

Ozempic and similar drugs, including Wegovy and Rybelsus (made by Novo Nordisk) and Trulicity and Mounjaro (made by Eli Lilly), are GLP-1 drugs initially approved for Type 2 diabetes treatment.

Their effectiveness in managing blood sugar levels has also led to their use in weight loss, with more than 15 million Americans reported using these drugs last month alone, with 40 times more prescriptions being written in 2023 than in 2018.

The lawsuit centers on allegations that the drug makers failed to adequately warn patients about serious gastrointestinal side effects, including gastroparesis, intestinal obstructions, and pancreatitis.

These adverse effects have been documented in recent studies and highlighted by the Food and Drug Administration (FDA).

Experts have said that this legal action contributes to an eroding public trust in both pharmaceutical companies and the FDA’s drug approval process.

A successful lawsuit could lead to increased scrutiny of GLP-1 agonists and similar drugs, potentially affecting their availability and use.

Weight-loss drugs have seen a dramatic increase in prescriptions, driven by endorsements from celebrities and widespread reports of their health benefits.

However, the ongoing litigation and associated negative publicity could dampen demand.

The outcome of this case may have far-reaching consequences for drug safety perceptions and the regulation of pharmaceuticals.

If you or a loved one used Ozempic or other similar drugs and subsequently developed stomach paralysis, ileus, or other health problems, you may be eligible to file a lawsuit. 

Contact the Ozempic Lawyers at TorHoerman Law for a free consultation. 

You can also use the chatbot on this page to find out if you qualify to file a claim instantly.

The Ozempic Lawsuit is growing, and more consumers are becoming aware of the serious side effects linked to GLP-1 medications. 

The U.S. Judicial Panel on Multidistrict Litigation (JPML) has assigned the litigation involving Ozempic, Wegovy, and Mounjaro to U.S. District Judge Karen Marston of the Eastern District of Pennsylvania.

This reassignment follows the untimely death of U.S. District Judge Gene E.K. Pratter.

The sprawling case, now under the management of Judge Marston, addresses over 10,000 personal injury claims.

The litigation focuses on severe allegations against Novo Nordisk and Eli Lilly and Co., who are accused of not providing adequate warnings regarding potential severe digestive side effects of these GLP-1 class medications.

These drugs, widely used for diabetes management and weight loss, have been linked by plaintiffs to serious conditions such as gastroparesis, severe vomiting, and bowel obstruction.

Key legal actions include finalizing the plaintiff’s fact sheet, which will detail claimants’ injuries and medical conditions, as well as their specific use of the drugs.

Defense lawyers view this stage as an opportunity to narrow the scope of the case by dismissing claims tied to counterfeit products or those lacking a proper diagnosis.

Plaintiffs’ attorneys, however, strongly oppose the premature dismissal of claims.

They are pushing for additional discovery and bellwether trials, aiming to investigate and resolve these cases thoroughly.

Judge Marston is anticipated to proceed given the high public profile of the case and its impact, considering that one in eight U.S. adults are reported to use these medications.

If you or a loved one used Ozempic or other similar drugs and subsequently developed stomach paralysis, ileus, or other health problems, you may be eligible to file a lawsuit. 

Contact the Ozempic Lawyers at TorHoerman Law for a free consultation. 

You can also use the chatbot on this page to find out if you qualify to file a claim instantly.

The Ozempic Lawsuit is growing, and more consumers are becoming aware of the serious side effects linked to GLP-1 medications. 

Growing concerns have emerged regarding the potential risks of gastroparesis associated with the use of GLP-1 receptor agonists such as Ozempic and Wegovy, commonly prescribed for obesity and diabetes management.

Gastroparesis, often referred to as stomach paralysis, is characterized by delayed gastric emptying, which can cause significant discomfort and complicate management of metabolic conditions.

Recent studies highlight the risk for gastroparesis subsequent to GLP-1 use: 

• Recent research presented at Digestive Disease Week 2024 highlights an increased occurrence of gastroparesis among patients administered GLP-1 drugs compared to those not on these medications.
• A study conducted by the University of Kansas analyzed health records from nearly 150,000 patients, revealing a 66% higher diagnosis rate of gastroparesis in those treated with GLP-1s.
• Further investigation by University Hospitals in Cleveland examined over 336,000 individuals, finding that the likelihood of developing gastroparesis escalates after six months of GLP-1 therapy.

While the overall risk remains below 1%, the data suggest a persistent increase relative to untreated individuals.

As Ozempic and Wegovy continue to be popular choices for managing diabetes and obesity, the ongoing research into their side effects like gastroparesis will remain a critical component of patient care.

Our lawyers are currently investigating cases of stomach paralysis and other serious side effects linked to these medications.

If you or a loved one used Ozempic or other similar drugs and subsequently developed stomach paralysis, ileus, or other health problems, you may be eligible to file a lawsuit. 

Contact the Ozempic Lawyers at TorHoerman Law for a free consultation. 

You can also use the chatbot on this page to find out if you qualify to file a claim instantly.  

Awareness surrounding Ozempic and other GLP-1 drugs continues to grow. 

The Ozempic multidistrict litigation (MDL) faces new challenges following the sudden and tragic death of the U.S. District Judge Gene E.K. Pratter on May 17, 2024.

Judge Pratter, aged 75, was overseeing the Ozempic MDL in the Eastern District of Pennsylvania at the time of his passing.

The loss of Judge Pratter may significantly impact the ongoing Ozempic lawsuits, which address severe gastrointestinal side effects linked to GLP-1 receptor agonists used in diabetes management and weight loss treatments.

With nearly 2% of the U.S. population prescribed these medications, the lawsuit is anticipated to escalate into a major mass tort.

These lawsuits allege that pharmaceutical companies, including Novo Nordisk, and Eli Lilly, did not sufficiently inform users about the risks associated with drugs like Ozempic, Wegovy, and Mounjaro.

As of May 1, 2024, there were 87 active lawsuits within the MDL, with potential growth to several thousand cases due to the drugs’ widespread usage.

The transition of these cases to a new presiding judge is now underway, which necessitates a comprehensive review of the existing records and a deep understanding of the related scientific and medical evidence.

This change may introduce delays in the proceedings. Moreover, an “Ozempic Science Day” scheduled for June 14, aimed at examining the scientific aspects of the litigation, now faces uncertainty.

If you or someone you know has developed gastroparesis or other health problems after taking Ozempic or other GLP-1 drugs may be eligible to file a lawsuit. 

Contact TorHoerman Law today for a free, no obligation consultation. 

For a free and instant case evaluation, use the chatbot on this page.

Awareness surrounding Ozempic and its serious side effects continues to grow. 

Ozempic, a widely used medication for weight loss, has been linked to a range of adverse effects.

A comprehensive analysis disclosed that over 9 million prescriptions for Ozempic were filled in the last quarter of 2022 alone.

However, the actual number of users might be even higher, as many people access the drug without appropriate medical supervision, often due to insurance limitations.

Our Ozempic lawyers are actively monitoring these developments, as reports of severe side effects continue to emerge.

Patients have reported conditions such as gastroparesis (stomach paralysis), gallbladder disease, and cyclic vomiting syndrome attributed to the use of Ozempic and other GLP-1 medications.

If you or someone you know has developed gastroparesis or other health problems after taking Ozempic or other GLP-1 drugs may be eligible to file a lawsuit. 

Contact TorHoerman Law today for a free, no obligation consultation. 

For a free and instant case evaluation, use the chatbot on this page.

The Ozempic lawsuit is ongoing. 

The Ozempic lawsuit is continuing through its initial phases within the Multidistrict Litigation (MDL) framework.

On May 9, 2024, U.S. District Judge Gene Pratter, based in Philadelphia, formally designated four attorneys to serve as lead counsel for the MDL against weight loss drug manufacturers Novo Nordisk and Eli Lilly.

This lawsuit is notable not only for the claims involved but also the method employed by Judge Pratter in selecting lead counsel.

His approach combines a self-nomination by potential lead counsels and subsequent approval through a consensus among fellow plaintiffs’ attorneys, a process that could influence future complex litigations.

Judge Pratter’s selection strategy is designed to efficiently manage the vast array of cases consolidated in the Ozempic MDL, ensuring effective representation and oversight.

As the litigation progresses, the focus intensifies on the alleged safety issues associated with these drugs.

Plaintiffs contend that not all side effects, particularly severe ones like stomach paralysis, were adequately disclosed, posing significant health risks to users.

Novo Nordisk asserts that Ozempic’s safety is thoroughly documented, with all potential side effects duly reported in compliance with regulatory standards.

Individuals who have experienced serious side effects such as stomach paralysis from Ozempic, Wegovy, or other GLP-1 receptor agonists, may have grounds for a claim.

If you or someone you know has developed gastroparesis or other health problems after taking Ozempic or other GLP-1 drugs may be eligible to file a lawsuit. 

Contact TorHoerman Law today for a free, no obligation consultation. 

For a free and instant case evaluation, use the chatbot on this page.

The current Ozempic and weight loss drug litigation is in its early stages, with more lawsuits anticipated as the court defines the parameters for case filings. 

An increasing number of individuals are filing lawsuits against pharmaceutical giants Eli Lilly and Novo Nordisk.

These companies produce a class of medications known as GLP-1 agonists, which include widely used diabetes and weight loss drugs such as Ozemic, Wegovy, Rybelsus, Trulicity, and Mounjaro.

Plaintiffs claim they suffered severe digestive issues, including gallbladder removal and gastroparesis, as a result of taking these medications.

The legal claims are centralized in Philadelphia under U.S. District Judge Gene E. K. Pratter due to the shared allegations concerning the drugs’ side effects.

The majority of the lawsuits specifically target Novo Nordisk, the maker of Ozempic and Wegovy, although the number of lawsuits could potentially rise into the thousands as more individuals come forward with claims of harm.

Novo Nordisk defends the safety and efficacy of its GLP-1 medications, emphasizing the drugs’ extensive market presence of 13 years and rigorous safety evaluations in collaboration with the U.S. Food and Drug Administration (FDA).

The litigation highlights the massive popularity of GLP-1 medications in the United States, both for diabetes management and weight loss.

With forecasts suggesting 30 million users by 2030 and sales surpassing $1 billion, the stakes are high for both the pharmaceutical industry and those alleging harm from these medications.

If you or someone you know has developed gastroparesis or other health problems after taking Ozempic or other GLP-1 drugs may be eligible to file a lawsuit. 

Contact TorHoerman Law today for a free, no obligation consultation. 

For a free and instant case evaluation, use the chatbot on this page.

February 19, 2024

The Ozempic lawsuit is ongoing, with over 55 lawsuits now consolidated into the Eastern District of Pennsylvania.

The Ozempic lawsuits target severe gastrointestinal injuries reportedly caused by Ozempic and other GLP-1 receptor agonist drugs, such as Eli Lilly’s Trulicity and Mounjaro.

The lawsuits claim that Novo Nordisk and Eli Lilly, prominent manufacturers of these drugs, did not sufficiently warn patients about the risk of serious side effects, including gastroparesis (delayed stomach emptying), intestinal obstruction, and other gastrointestinal issues.

Plaintiffs argue that although the drug labels contained warnings, the pharmaceutical companies downplayed the potential severity of the gastrointestinal issues.

The MDL includes cases related to various medications, including Novo Nordisk’s Ozempic, Wegovy, Rybelsus, and Eli Lilly’s Trulicity and Mounjaro.

Recently, a federal judge in Louisiana largely denied Novo Nordisk’s motion to dismiss the lawsuit, particularly the claims concerning inadequate warnings about the risk of gastroparesis, allowing these cases to proceed.

If you or a loved one have suffered from severe gastroparesis, bowel obstruction, or other health problems after taking Ozempic or other similar drugs, you may be eligible to file an Ozempic Lawsuit.

Contact the Ozempic Lawyers at TorHoerman Law for a free consultation.

You can also use the chatbot on this page for a free case review to find out if you qualify to file an Ozempic Lawsuit instantly.

Lawsuits against Ozempic and other GLP-1 drugs are increasing. 

Lawsuits against Novo Nordisk, the pharmaceutical giant behind Ozempic, continue to mount as more individuals report severe side effects from the drug.

Ozempic, widely used for blood sugar regulation and weight loss, faces scrutiny over its safety after numerous patients experienced significant health issues.

An Illinois resident, aged 60, recently filed a claim stating that Ozempic caused a blocked bowel and violent vomiting, resulting in a torn esophagus and a subsequent week-long hospital stay.

This case adds to the growing number of legal actions challenging the safety of Ozempic and Wegovy, another drug produced by Novo Nordisk.

Both Ozempic and Wegovy are formulated to aid in weight management and improve pancreatic function by increasing insulin production.

However, nearly 60 plaintiffs have now alleged that these medications led to stomach paralysis or other severe conditions. The accumulation of cases has prompted the consolidation of these lawsuits in a federal court in Pennsylvania.

This centralization aims to streamline the legal process as more individuals come forward with similar allegations.

Individuals who have developed gastroparesis after taking Ozempic or other GLP-1 drugs may be eligible to file a lawsuit. 

Contact TorHoerman Law or use the chatbot on this page to find out if you qualify for the Ozempic Lawsuit.

The Ozempic Litigation is ongoing and our lawyers are still accepting more cases.

There are a total of seven Ozempic Lawsuits pending in the newly created MDL according to the most recent JPML filings.

Multi-District Litigations (MDLs) are legal procedures in the United States designed to handle multiple related civil lawsuits that involve similar issues, facts, or defendants.

When numerous individuals or entities file lawsuits related to a common set of circumstances, such as health problems linked to Ozempic and other semaglutide medications, these cases can be consolidated into a single federal district court for pretrial proceedings.

MDLs aim to streamline the litigation process by centralizing the discovery process, reducing duplication of efforts, and ensuring consistent rulings on key legal issues.

Individuals who have developed gastroparesis after taking Ozempic or other GLP-1 drugs may be eligible to file a lawsuit. 

Contact TorHoerman Law or use the chatbot on this page to find out if you qualify for the Ozempic Lawsuit.